Research data show that weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.
Maryam Akintoye, PharmD Candidate
Advertisement
Articles by Maryam Akintoye, PharmD Candidate
Pharmacists play an important role in managing patients with this complex condition.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5